By conjugating PD-L1 and CTLA-4 inhibitors, as well as cytokines like IL-2, with a collagen-binding motif derived from the von Willebrand factor A3 domain, these agents can be selectively delivered to tumor sites, improving treatment specificity and efficacy 899,900. Here, CD274 is linked to neoplasm.